Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis

Ingenuity Systems and Pfizer Pharmaceuticals, Inc. have announced a strategic partnership. This new multi-year partnership promotes enterprise-wide deployment of IPA, enabling more researchers to use IPA for the exploration, interpretation, and analysis of life science information.

In addition, Pfizer will integrate IPA and content from the Ingenuity knowledge base with other informatics solutions used throughout the Pfizer organization.

"We have selected Ingenuity as a partner to support our vision to implement an integrated and enterprise-scale pathway solution," stated Giles Day, Senior Director of the Targets and Mechanisms Informatics Group, Pfizer.

"Through IPA, our internal scientists can access quality information to model and analyze complex biological and chemical systems and effectively share the information seamlessly across the organization. Our goal is to ensure our teams are selecting the best disease targets so that they will have higher confidence in the drug's mechanism of action and safety,” Day said.

"In addition to IPA, we have been able to offer a suite of powerful capabilities tailored specifically for Pfizer," stated Jake Leschly, CEO, Ingenuity Systems. "By integrating IPA with internal platforms, scientists are primed to unlock new insights from their data and internal information, and are more equipped to make faster, data-based decisions about targets. Multiple groups within Pfizer can now leverage IPA to rapidly make connections between pathways and their role in diseases, and then communicate results across the organization. We are very excited to be working with Pfizer on such a visionary program."